GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

The FDA has accepted GSK’s application for priority review of gepotidacin, a first-in-class antibiotic for uncomplicated ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer ...

The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new sector-specific tariffs ...

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.

At Axtria Ignite 2025 in Princeton, New Jersey, editor-in-chief Jonah Comstock connected with GSK's SVP of enterprise AI and chief digital and technology officer, commercial, Madhavi Ramakrishna.

Spero Therapeutics, Inc. (NASDAQ: SPRO) Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...